Transdermal Delivery Offer for Low-Dose Acetylsalicylic Acid

The use of Acetyl Salicylic Acid (ASA) in the secondary prevention of cardio vascular diseases is well known. Orally administered ASA is rapidly metabolized to its principal metabolite Salicylic Acid (SA) in the gastrointestinal fluids, during absorption in the intestine and liver. ASA, and not its hydrolysis product SA, which exhibits antithrombotic activity. Transdermal delivery of acetylsalicylic acid is a safe and convenient alternative, especially during long-term use. The goal of present study was to design transdermal delivery system, using Eudragit E100 weak organic acid and plasticizer. The influence of different dissolution medium for preparation of model systems, the type and amount of cross-linking agents and plasticizer on the release of acetylsalicylic acid was investigated. Matrix systems were prepared by solvent casting method. The dissolution study was carried out in water for 72 hours by disk assembly method paddle and in-vitro release of acetylsalicylic acid from loaded model systems was studied. Quantitative determination of released acetylsalicylic acid by UV spectroscopy at wavelength of 265 nm was made. Significantly sustained release show systems prepared by using water as dissolution medium, MA, like cross linking agent, PEG400 like plasticizer.